Key Takeaways
- •A large retrospective study published in JAMA Network Open reports that GLP-1 receptor agonist use correlates with better survival and recurrence results in adult women with breast cancer who have obesity or type 2 diabetes.
- •Women with breast cancer who also deal with obesity or type 2 diabetes tend to have poorer results compared to those without these conditions.
- •The team drew from the TriNetX US Collaborative Network, pinpointing 841,831 adult women with breast cancer from 68 healthcare organizations.
GLP-1 Receptor Agonists Associated with Improved Breast Cancer Outcomes
A large retrospective study published in JAMA Network Open reports that GLP-1 receptor agonist use correlates with better survival and recurrence results in adult women with breast cancer who have obesity or type 2 diabetes. Researchers analyzed data from a massive dataset, highlighting effects that go past blood sugar management and weight reduction. These observational results show strong associations, yet they call for cautious review due to the study's non-randomized nature.
Reasons for Studying This Connection
Women with breast cancer who also deal with obesity or type 2 diabetes tend to have poorer results compared to those without these conditions. GLP-1 receptor agonists serve as common treatments for diabetes and obesity, with their prescriptions rising quickly in recent years. Prior lab studies hint at potential anti-cancer actions, and shedding weight alone might aid long-term results, prompting checks on whether using these drugs near or post-diagnosis ties to reduced overall death rates and better time without cancer return.
Study Methods and Patient Groups
The team drew from the TriNetX US Collaborative Network, pinpointing 841,831 adult women with breast cancer from 68 healthcare organizations. They applied 1:1 propensity score matching to form balanced groups for three main comparisons. One group pitted GLP-1 receptor agonist users against non-users in breast cancer patients with obesity but no type 2 diabetes; another matched them to insulin or metformin users with type 2 diabetes; the third compared to SGLT2 inhibitor users with type 2 diabetes.
Primary measures included all-cause mortality, while secondary focused on recurrence-free survival across a 10-year period. This setup aimed to tackle detailed questions beyond basic user versus non-user setups. Active comparisons with drugs like insulin, metformin, and SGLT2 inhibitors helped limit common biases in backward-looking studies, though the authors stress that such data cannot prove cause and effect.
Strong Results in Breast Cancer with Obesity
In the group with breast cancer and obesity, GLP-1 receptor agonist use tied to much lower risk of death from any cause versus non-use, with an unadjusted hazard ratio of 0.35 that held up after adjustments. Recurrence-free survival also improved, showing an unadjusted hazard ratio of 0.44 and significant adjusted links. Five-year and 10-year survival rates in this matched obesity group leaned toward those using GLP-1 receptor agonists, pointing to a possible lasting tie between the drugs and better results.
These obesity findings stand out for suggesting overlap between metabolic treatments and cancer results. However, backward studies using electronic health records pick up real-world links but face risks from leftover biases, choices in treatment, care access differences, and unseen disease factors.
Outcomes in Type 2 Diabetes Patients
Comparisons in type 2 diabetes cases showed even sharper benefits for GLP-1 receptor agonists over insulin or metformin. Users had lower all-cause mortality risk, with an unadjusted hazard ratio of 0.09, and fewer recurrence events, at 0.33 unadjusted, both staying significant post-adjustment. Such low ratios prove rare in non-randomized studies near oncology, making them compelling yet hard to take fully without doubt.
One view sees GLP-1 receptor agonists aiding breast cancer results biologically through weight loss, insulin control, heart benefits, and inflammation changes. The study design sought to minimize flaws, but full causality remains unproven. These signals urge more targeted trials to confirm the patterns.
